ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

MANAGEMENT REPORT

Management's Responsibility for Financial Reporting

The accompanying financial statements have been prepared by Mackenzie Financial Corporation, as Manager of Mackenzie FuturePath Shariah Global Equity Fund (the "Fund"). The Manager is responsible for the integrity, objectivity and reliability of the data presented. This responsibility includes selecting appropriate accounting principles and making judgments and estimates consistent with IFRS Accounting Standards. The Manager is also responsible for the development of internal controls over the financial reporting process, which are designed to provide reasonable assurance that relevant and reliable financial information is produced.

The Board of Directors (the "Board") of Mackenzie Financial Corporation is responsible for reviewing and approving the financial statements and overseeing the Manager's performance of its financial reporting responsibilities. The Board meets regularly with the Manager, internal auditors and external auditors to discuss internal controls over the financial reporting process, auditing matters and financial reporting issues.

KPMG LLP is the external auditor of the Fund. It is appointed by the Board. The external auditor has audited the financial statements in accordance with Canadian generally accepted auditing standards to enable it to express to the securityholders its opinion on the financial statements. Its report is set out below.

On behalf of Mackenzie Financial Corporation,

Manager of the Fund

Luke Gould
President and Chief Executive Officer

Terry Rountes
Chief Financial Officer, Funds

Leg Nos

June 4, 2024

INDEPENDENT AUDITOR'S REPORT

To the Securityholders of Mackenzie FuturePath Shariah Global Equity Fund (the "Fund")

Opinion

We have audited the financial statements of the Fund, which comprise:

- the statements of financial position as at March 31, 2024 and March 31, 2023
- the statements of comprehensive income for the periods then ended as indicated in note 1
- the statements of changes in financial position for the periods then ended as indicated in note 1
- . the statements of cash flows for the periods then ended as indicated in note 1 and
- notes to the financial statements, including a summary of material accounting policies (Hereinafter referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Fund as at March 31, 2024 and March 31, 2023, and its financial performance and cash flows for the periods then ended as indicated in note 1 in accordance with IFRS Accounting Standards.

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Statements" section of our auditor's report.

We are independent of the Fund in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

INDEPENDENT AUDITOR'S REPORT (cont'd)

Other Information

Management is responsible for the other information. Other information comprises:

- the information included in the Annual Management Report of Fund Performance of the Fund filed with the relevant Canadian Securities Commissions.

Our opinion on the financial statements does not cover the other information and we do not and will not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit and remain alert for indications that the other information appears to be materially misstated.

We obtained the information included in the Annual Management Report of Fund Performance of the Fund filed with the relevant Canadian Securities Commissions as at the date of this auditor's report. If, based on the work we have performed on this other information, we conclude that there is a material misstatement of this other information, we are required to report that fact in the auditor's report.

We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRS Accounting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Fund's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Fund or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the financial reporting process of the Fund.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.
 - The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an
 opinion on the effectiveness of the internal control.
- · Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Fund's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Fund to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Chartered Professional Accountants, Licensed Public Accountants Toronto. Canada

June 4, 2024

LPMG LLP

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

STATEMENT OF FINANCIAL POSITION

at March 31 (in \$ 000 except per security amounts)

	2024
	\$
ASSETS	
Current assets	
Investments at fair value	7,702
Cash and cash equivalents	492
Dividends receivable	8
Accounts receivable for investments sold	82
Accounts receivable for securities issued	
Total assets	8,284
LIABILITIES	
Current liabilities	
Accounts payable for investments purchased	27
Accounts payable for securities redeemed	274
Due to manager	8
Total liabilities	309
Net assets attributable to securityholders	7,975

Net assets attributable to securityholders (note 3)

	per security	per series
	2024	2024
Series PA	12.39	6,640
Series PH	12.43	1,335
		7,975

STATEMENT OF COMPREHENSIVE INCOME

for the period ended March 31 (in \$ 000 except per security amounts)

	2024 \$
Income	•
Dividends	59
Other changes in fair value of investments and other	
net assets	
Net realized gain (loss)	172
Net unrealized gain (loss)	1,323
Total income (loss)	1,554
Expenses (note 6)	
Management fees	52
Administration fees	68
Commissions and other portfolio transaction costs	12
Independent Review Committee fees	_
Expenses before amounts absorbed by Manager	132
Expenses absorbed by Manager	50
Net expenses	82
Increase (decrease) in net assets attributable to	_
securityholders from operations before tax	1,472
Foreign withholding tax expense (recovery)	7
Foreign income taxes paid (recovered)	
Increase (decrease) in net assets attributable to	
securityholders from operations	1,465

Increase (decrease) in net assets attributable to securityholders from operations (note 3)

	per security	per series
	2024	2024
Series PA	2.40	1,371
Series PH	3.38	94
		1,465

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

STATEMENT OF CHANGES IN FINANCIAL POSITION

for the period ended March 31 (in \$ 000 except per security amounts)

	Total 2024	Series PA 2024	Series PH 2024
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS			
Beginning of period	_	_	_
Increase (decrease) in net assets from operations	1,465	1,371	94
Distributions paid to securityholders:			
Investment income	_	_	_
Capital gains			
Total distributions paid to securityholders	_		
Security transactions:			
Proceeds from securities issued	9,705	8,212	1,493
Reinvested distributions	-	_	-
Payments on redemption of securities	(3,195)	(2,943)	(252)
Total security transactions	6,510	5,269	1,241
Increase (decrease) in net assets attributable to securityholders	7,975	6,640	1,335
End of period	7,975	6,640	1,335
Increase (decrease) in fund securities (in thousands) (note 7):		Securities	Securities
Securities outstanding – beginning of period		_	_
Issued		792	128
Reinvested distributions		_	_
Redeemed		(256)	(21)
Securities outstanding – end of period		536	107

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

STATEMENT OF CASH FLOWS

for the period ended March 31 (in \$ 000)

	2024 \$
Cash flows from operating activities	Ψ
Net increase (decrease) in net assets attributable to	
securityholders from operations	1,465
Adjustments for:	
Net realized loss (gain) on investments	(176)
Change in net unrealized loss (gain) on investments	(1,323)
Purchase of investments	(10,696)
Proceeds from sale and maturity of investments	4,438
(Increase) decrease in accounts receivable and other assets	(8)
Increase (decrease) in accounts payable and other liabilities	8
Net cash provided by (used in) operating activities	(6,292)
Cash flows from financing activities	
Proceeds from securities issued	9,025
Payments on redemption of securities	(2,241)
Distributions paid net of reinvestments	
Net cash provided by (used in) financing activities	6,784
Net increase (decrease) in cash and cash equivalents	492
Cash and cash equivalents at beginning of period	_
Effect of exchange rate fluctuations on cash and cash	
equivalents	400
Cash and cash equivalents at end of period	492
Cash	492
Cash equivalents	492
Cash and cash equivalents at end of period	492
Cash and Cash equivalents at end of period	432
Supplementary disclosures on cash flow from operating activities:	
Dividends received	51
Foreign taxes paid	7
Interest received	/
	_
Interest paid	

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

SCHEDULE OF INVESTMENTS

as at March 31, 2024

	Country	Sector	Par Value/ Number of Shares/Units	Average Cost (\$ 000)	Fair Value (\$ 000)
EQUITIES					
AbbVie Inc.	United States	Health Care	276	51	68
Adobe Systems Inc.	United States	Information Technology	5	3	3
Advance Auto Parts Inc.	United States	Consumer Discretionary	521	53	60
Agilent Technologies Inc.	United States	Health Care	113	22	22
Alamos Gold Inc.	Canada	Materials	1,629	29	33
Alkermes PLC	United States	Health Care	668	25	24
Alphabet Inc. Class A	United States	Communication Services	1,704	278	348
Amazon.com Inc.	United States	Consumer Discretionary	1,478	264	361
Apple Inc.	United States	Information Technology	2,114	527	491
Applied Materials Inc.	United States	Information Technology	338	63	94
ASML Holding NV	Netherlands	Information Technology	24	27	31
Astellas Pharma Inc.	Japan	Health Care	3,700	68	54
Atlassian Corp. PLC Class A	United States	Information Technology	207	55	55
Baker Hughes Co.	United States	Energy	520	22	24
Binggrae Co. Ltd.	South Korea	Consumer Staples	187	10	10
Booking Holdings Inc.	United States	Consumer Discretionary	16	57	79
Boryung Pharmaceutical Co. Ltd.	South Korea	Health Care	1,442	18	19
Boyd Group Services Inc.	Canada	Industrials	171	43	49
Bristol-Myers Squibb Co.	United States	Health Care	489	34	36
Broadcom Inc.	United States	Information Technology	92	125	165
Buzzi Unicem SPA	Italy	Materials	810	32	43
Cardinal Health Inc.	United States	Health Care	194	24	29
carsales.com Ltd.	Australia	Communication Services	1,796	57	57
Chong Kun Dang Pharmaceutical Corp.	South Korea	Health Care	78	9	9
Cisco Systems Inc.	United States	Information Technology	997	68	67
The Coca-Cola Co.	United States	Consumer Staples	790	64	65
Cochlear Ltd.	Australia	Health Care	72	22	21
Codan Ltd.	Australia	Information Technology	1,419	13	14
Colgate Palmolive Co.	United States	Consumer Staples	598	62	73
ComfortDelGro Corp. Ltd.	Singapore	Industrials	7,500	9	11
Computacenter PLC	United Kingdom	Information Technology	18	1	1
Contact Energy Ltd.	New Zealand	Utilities	2,306	16	16
Core & Main Inc.	United States	Industrials	898	48	70
CRH PLC (London Shares)	Ireland	Materials	318	36	37
Crowdstrike Holdings Inc.	United States	Information Technology	129	40	56
D.R. Horton Inc.	United States	Consumer Discretionary	320	49	71
Daiichi Sankyo Co. Ltd.	Japan	Health Care	200	9	9
Demant AS	Denmark	Health Care	145	10	10
Deterra Royalties Ltd.	Australia	Materials	8,767	39	38
Devon Energy Corp.	United States	Energy	120	8	8
Docebo Inc.	Canada	Information Technology	360	25	24
DocuSign Inc.	United States	Information Technology	279	22	23
DongKook Pharmaceutical Co. Ltd.	South Korea	Health Care	868	16	15
Dropbox Inc. Class A	United States	Information Technology	1,791	59	59
Ecolab Inc.	United States	Materials	23	6	7
Eli Lilly and Co.	United States	Health Care	67	63	71
EOG Resources Inc.	United States	Energy	75	12	13
Experian PLC	United States	Industrials	877	45	52
Gaztransport Et Technigaz SA	France	Energy	61	13	12
General Electric Co.	United States	Industrials	401	58	95
General Mills Inc.	United States	Consumer Staples	244	21	23
Genmab AS	Denmark	Health Care	48	19	20
Gilead Sciences Inc.	United States	Health Care	361	37	36
GlaxoSmithKline PLC	United States United Kingdom	Health Care	3,223	74	94
Grafton Group PLC	United Kingdom	Industrials	3,223 1,444	74 25	25
H. Lundbeck AS	Denmark	Health Care	2,465	25 15	16
Hana Tour Service Inc.	South Korea	Consumer Discretionary	2,465	15	14
Hanwha Systems Co. Ltd.	South Korea	Industrials	2,426	43	14 42
The Home Depot Inc.	United States	Consumer Discretionary	2,426 105	43 52	42 55
Hosiden Corp.		Information Technology	600	10	10
Incyte Corp.	Japan United States	Health Care	370	30	29
Independence Group NL	Onited States Australia	Health Care Materials	370 424	30	29 3
Insperity Inc.	United States	Industrials	378	49	56
поронцу по.	Office States	iliuustildis	3/0	43	JU

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

SCHEDULE OF INVESTMENTS (cont'd)

as at March 31, 2024

Feet Communication Commu		Country	Sector	Par Value/ Number of Shares/Units	Average Cost (\$ 000)	Fair Value (\$ 000)
Number States Information Technology 51 38 85 85 85 85 85 85 85	EQUITIES (cont'd)					
MA-Frence Corp. United States Information Technology 51 36 Korea Electric Terminal Co. Ltd. South Korea Information Technology 67 66 Lennar Corp. Class A United States Information Technology 67 66 Lennar Corp. Class A United States Information Technology 67 66 Lennar Corp. Class A United States Information Technology 67 68 Lennar Corp. Class A United States Information Technology 67 68 Lennar Corp. Class A United States Information Technology 67 72 Market Carl Information Technology 67 72 Market Carl Information Technology 67 69 Market Platforms Inc. Class A United States Information Technology 1367 35 Market Platforms Inc. Class A United States Information Technology 1367 35 Market Platforms Inc. Class A United States Information Technology 137 35 Market Market Carl Information Technology 137 35 Market Mark	Intel Corp.	United States	Information Technology	1.586	71	95
Lam Research Corp. United States Information Technology 67 56	•	United States		,	36	48
Lennar Corp. Class A United States Consumer Discretionary 126 25	Korea Electric Terminal Co. Ltd.	South Korea	Industrials	232	16	15
Lundin Cold Inc. Canada Materials 267 4	Lam Research Corp.	United States	Information Technology	67	56	88
MasterCard Inc. Class A United States Financials 204 109 109 109 100	Lennar Corp. Class A	United States	Consumer Discretionary	126	25	29
Medrosn PLC	Lundin Gold Inc.	Canada	Materials	267	4	5
MEG Energy Corp. Canada Energy (2,25) 59 Merck & Co. Inc. United States Health Care 6,338 50 Merck & Co. Inc. United States Communication Services 380 168 Micron Ecknology Inc. United States Information Technology 387 35 Micron Ecknology Inc. United States Information Technology 387 35 Micros Corp. United States Information Technology 387 35 Novatirs As P. Switzerland Health Care 333 43 Novatirs As P. Demmark Health Care 333 43 Nutrai Kin. Class A United States Information Technology 79 29 NUDIDA Corp. United States Information Technology 79 226 Usual Asia Machania Health Care 200 11 Patron Co. Ltd. South Korea Information Technology 79 226 Problem Co. United States Consumer States 322 80	MasterCard Inc. Class A	United States	Financials	204	109	133
Melrose Industries PLC	Medtronic PLC	United States	Health Care	638		75
Merola R. Co. Inc.	MEG Energy Corp.	Canada	Energy			70
Mate Pathorms Inc. Class A United States United States Information Echnology 367 35	Melrose Industries PLC	United Kingdom	Industrials	6,338		73
Micros Technology Inc.	Merck & Co. Inc.	United States	Health Care	652	96	117
Microsoft Copp.	Meta Platforms Inc. Class A	United States	Communication Services	380	168	250
Novaris AS Reg. Switzerland Health Care 333 43	Micron Technology Inc.	United States	Information Technology	387	35	62
Now Dordisk ÅS Demmark Health Care 892 98 NUDIA Corp. United States Information Technology 295 226 Osuka Holdings Co. Ltd. Japan Health Care 200 11 Partron Co. Ltd. South Korea Information Technology 1,142 10 Pepsico Inc. United States Carsumer Staples 323 80 Pitzer Inc. United States Carsumer Staples 202 7 Pro Medicus Ltd. Australia Health Care 274 20 The Protec & Ltd. Sush Korea Information Technology 341 14 PKI Inc. South Korea Information Technology 341 14 PKI Inc. South Korea Information Technology 341 14 Putted Group Inc. United States Information Technology 342 44 Putted Found Inc. United States Information Technology 376 69 Region Resources Ltd. Australia Metralia Metralia 17	Microsoft Corp.	United States	Information Technology	1,106	516	629
Nutanik Inc. Class A	Novartis AG Reg.	Switzerland	Health Care	333	43	44
NVDIA Corp. United States Information Echnology 295 226	Novo Nordisk AS B	Denmark	Health Care	892		154
NVDIA Corp. United States Information Technology 295 226	Nutanix Inc. Class A	United States	Information Technology	797	29	67
Disuba Holdings Co. Ltd. Japan Health Care 200 11	NVIDIA Corp.					361
Partron Co. Ltd. South Korea Information Technology 1,142 10						11
PepsEcol Inc.		•	Information Technology	1.142	10	9
Pitzer Inc. United States Health Care 202 7 Pro Medicus Ltd. Australia Health Care 274 20 The Procter & Gamble Co. United States Consumer Staples 559 113 Protec Co. Ltd. South Korea Information Technology 708 14 PKI Koroup Inc. United States Consumer Discretionary 435 44 PulleGroup Inc. United States Information Technology 708 17 PulleGroup Inc. United States Information Technology 376 69 Regis Resources Ltd. Australia Materials 9,644 17 RELV PLC United States Information Technology 376 69 Republic Services Inc. United States Information Technology 376 69 SAP Global Inc. United States Information Technology 13 63 Salesforce Inc. United States Information Technology 108 30 Salmar ASA No way Consumer Staples 386	PepsiCo Inc.					77
Po Medicius Ltd.						8
The Procter & Gamble Co. United States Consumer Staples 559 113						25
Protec Co. Ltd. South Korea						123
PSK Inc. South Korea Information Technology 708 17						18
Pute Forogo Inc. United States Consumer Discretionary 435 44 Pure Storage Inc. United States Information Technology 322 45 Qualcomm Inc. United States Information Technology 376 69 Regis Resources Ltd. Australia Materials 9,644 17 RELX PLC United States Industrials 247 49 SkP Global Inc. United States Information Technology 108 30 Salesforce Inc. United States Information Technology 108 30 Salmar ASA Norway Consumer Staples 386 33 Samsung Electronics Co. Ltd. South Korea Information Technology 111 8 Sandoz Group AG Svitzerland Health Care 645 29 Santen Pharmaceutical Co. Ltd. Japan Health Care 18 3 Segyung Hitech Co. Ltd. Subaryang Hitech						21
Pure Starage Inc. United States Information Technology 92.2 45 Qualcomm Inc. United States Information Technology 376 69 Regis Resources Ltd. Australia Materials 9,644 17 RELX PLC United Kingdom Industrials 1,139 55 Republic Services Inc. United States Industrials 247 49 S&P Global Inc. United States Information Technology 108 30 Sallesforce Inc. United States Information Technology 118 30 Salles Core Inc. United States Information Technology 111 8 Sales Torou AG Norway Consumer Staples 386 33 Samsung Electronics Co. Ltd. South Korea Information Technology 111 8 Sandoz Group AG Switzerland Health Care 665 29 Sante Darre Darre Darre Device Ltd. Japan Health Care 18 3 Seyungh Ritich Co. Ltd. South Korea Information Technology						71
Qualcomm Inc. United States Information Technology 376 69 Regis Resources Ltd. Australia Materials 9,644 17 RELX PLC United Kingdom Industrials 1,139 55 Republic Services Inc. United States Industrials 247 49 SAP Global Inc. United States Information Technology 108 30 Salesforce Inc. United States Information Technology 108 30 Salmar ASA Norway Consumer Staples 386 33 Samotog Group AG Switzerland Health Care 645 29 Sandoz Group AG Switzerland Health Care 645 29 Sareta Pharmaceutical Co. Ltd. Japan Health Care 700 9 Sareta Pharmaceutical Co. Ltd. South Korea Information Technology 1,545 15 SIA Engineering Co. Ltd. Singapore Information Technology 1,545 15 SIA Engineering Co. Ltd. Singapore Information Technology 61<						65
Regis Resources Ltd. RELX PLC United Kingdom Relx PLC United Kingdom Relx PLC United Kingdom Relx PLC United States Industrials 1,139 55 Republic Services Inc. United States Industrials 1247 49 S&P Global Inc. United States Information Technology 108 30 Salmar ASA Norway Consumer Staples 386 33 Samsung Electronics Co. Ltd. South Korea Information Technology 1111 88 Sandou Group AG Sandou Group AG South Korea Sandou Group AG South Korea Sandou Froup AG Santen Pharmaceutical Co. Ltd. Japan Health Care 188 389 Segyung Hitech Co. Ltd. Japan Health Care 188 389 Segyung Hitech Co. Ltd. South Korea Information Technology 1,545 15 SIA Engineering Co. Ltd. Singapore Industrials 6,300 15 SWyworks Solutions Inc. United States Information Technology 61 9 Stantec Inc. Canada Information Technology 61 19 Stantec Inc. Canada Information Technology 60 13 Team Viewer AG Germany Information Technology 60 13 The TJK Companies Inc. United States Consumer Staples 337 63 Iteam Viewer AG Germany Information Technology 60 13 The TJK Companies Inc. United States Consumer Discretionary 395 48 Trelleborg AB Sweden Information Technology 60 13 The TJK Companies Inc. United States Consumer Discretionary 395 48 Trelleborg AB Sweden Information Technology 60 35 Under Technologies Inc. United States Consumer Discretionary 4,086 40 Valero Fergy Corp. United States Financials 318 102 Virech Holdings Ltd. Hong Kong Information Technology 900 7 Virech Holdings Ltd. Hong Kong Information Technology 900 7 Virech Holdings Ltd. Hong Kong Information Technology 900 7 Virech Holdings Ltd. Hong Kong Information Technology 900 7 Virech Holdings Ltd. Hong Kong Information Technology 900 7 Virech Holdings Ltd. Hong Kong Information Technology 900 7 Virech Holdings Ltd. Hong Kong Information Technology 900 7 Virech Holdin	•					86
RELY PLC Republic Services Inc. United States Republic Services Inc. United States Industrials I19 63 Salesforce Inc. United States Information Technology I108 30 Salesforce Inc. United States Information Technology I108 30 Salmar ASA Norway Consumer Staples 386 33 Samsung Electronics Co. Ltd. South Korea Information Technology I111 8 Sandoz Group AG Switzerland Health Care 645 29 Santen Pharmaceutical Co. Ltd. Japan Health Care 18 33 Segyung Hitech Co. Ltd. South Korea Information Technology I111 8 Sarphy I111 8 Sarphy I111 8 Sandoz Group AG Switzerland Health Care 645 29 Saret Paramaceutical Co. Ltd. Japan Health Care 18 33 Segyung Hitech Co. Ltd. South Korea Information Technology I1,545 I5 SIN A Engineering Co. Ltd. South Korea Information Technology I1,545 I5 SIN A Engineering Co. Ltd. Singapore Industrials 6,300 I5 Skyworks Solutions Inc. United States Information Technology I1,545 I5 SIN A Engineering Co. Ltd. Singapore Industrials I						17
Republic Services Inc. United States Industrials SAP Global Inc. United States Information Technology 108 30 Salmar ASA Norway Consumer Staples 386 33 Samsung Electronics Co. Ltd. South Korea Information Technology 111 8 Sandoz Group AG Switzerland Health Care 645 29 Santen Pharmaceutical Co. Ltd. Japan Health Care 188 33 Segyung Mitech Co. Ltd. South Korea Information Technology 111 8 Sandoz Group AG Switzerland Health Care 645 29 Santen Pharmaceutical Co. Ltd. Japan Health Care 188 33 Segyung Mitech Co. Ltd. South Korea Information Technology 1,545 15 SIA Engineering Co. Ltd. South Korea Information Technology 1,545 15 SIA Engineering Co. Ltd. Slik Engineeri				,		67
S&P Global Inc.United StatesFinancials11963Salesforce Inc.United StatesInformation Technology10830Salmar ASANorwayConsumer Staples38633Samsung Electronics Co. Ltd.South KoreaInformation Technology1118Sandoz Group AGSwitzerlandHealth Care64529Santen Pharmaceutical Co. Ltd.JapanHealth Care7009Sarepta Therapeutics Inc.United StatesHealth Care183Segvung Hiteler Co. Ltd.South KoreaInformation Technology1515SIA Engineering Co. Ltd.South KoreaInformation Technology619Skyworks Solutions Inc.United StatesInformation Technology619Skyworks Solutions Inc.United StatesInformation Technology619Stantec Inc.CanadaInformation Technology619States Corp.JapanConsumer Discretionary2,40060Target Corp.United StatesConsumer Staples33763TeamViewer AGGermanyInformation Technology6013The TJX Companies Inc.United StatesInformation Technology6013The TJX Companies Inc.United StatesInformation Technology6013The TJX Companies Inc.United StatesConsumer Discretionary39548Trelleborg ABSwedenIndustrials82159Uber Technologies						64
Salesforce Inc. United States Norway Consumer Staples 386 33 Samsung Electronics Co. Ltd. South Korea Information Technology Ill 8 Sandoz Group AG Samtung Electronics Co. Ltd. South Korea Information Technology Ill 8 Sandoz Group AG Switzerland Health Care 645 29 Santen Pharmaceutical Co. Ltd. Japan Health Care 700 9 Sarepta Therapeutics Inc. United States Health Care 18 3 Segyung Hitech Co. Ltd. South Korea Information Technology I,545 I5 SIA Engineering Co. Ltd. South Korea Information Technology I,545 I5 SIA Engineering Co. Ltd. Singapore Industrials G,300 I5 Skyworks Solutions Inc. United States Information Technology I,545 I6 9 Stantec Inc. Stantec Inc. Stantec Inc. Japan Consumer Discretionary Consumer Staples Consumer Staples Consumer Staples Information Technology I,545 I6 9 Stantec Inc. Japan Consumer Discretionary Consumer Staples Information Technology I,545 I6 9 Stantec Inc. Japan Consumer Discretionary Consumer Staples Information Technology Inc. Japan Information Technology Information Technology Inc. Japan Information Technology Information Technol	•					69
Salmar ASA Samsung Electronics Co. Ltd. South Korea Information Technology III 8 Samsung Electronics Co. Ltd. South Korea Information Technology III 8 Sandoz Group AG Switzerland Health Care Ford Sarepta Therapeutics Inc. Information Technology III 8 Sarepta Therapeutics Inc. Information Technology III 8 Sarepta Therapeutics Inc. Information Technology III 8 Sarepta Therapeutics Inc. III 8 3 Seyung Hitter Lo. Ltd. South Korea Information Technology III 8 SIA Engineering Co. Ltd. Singapore Industrials Information Technology III 9 Styworks Solutions Inc. III 19 Styworks Solutions Inc. III 20 Intel States Information Technology III 19 Industrials III 19 Industrials III 19 Industrials III 19 Information Technology III 10 Intel States Information Incustrials III 10 III						44
Samsung Electronics Co. Ltd. Sandoz Group AG Switzerland Sandoz Group AG Switzerland Sandoz Group AG Sarepta Health Care Fore Sarepta Therapeutics Inc. United States Information Technology Information Techn						34
Sandoz Group AG Santen Pharmaceutical Co. Ltd. Japan Health Care 645 29 Santen Pharmaceutical Co. Ltd. Japan Health Care 18 3 Segyung Hitech Co. Ltd. United States Health Care 18 3 Segyung Hitech Co. Ltd. South Korea Information Technology 1,545 15 SIA Engineering Co. Ltd. Singapore Industrials 6,300 15 Skyworks Solutions Inc. United States Information Technology 61 9 Stantec Inc. Canada Information Technology 65 9 Stantec Inc. Canada Information Technology 65 9 Stantec Inc. Canada Information Technology 66 9 Stantec Inc. Canada Information Technology 65 9 Stantec Inc. Canada Information Technology 66 9 Stantec Inc. Canada Information Technology 66 9 Stantec Inc. Canada Information Technology 2,020 60 Target Corp. United States Consumer Staples 337 63 Team Viewer AG Germany Information Technology 2,023 40 Texas Instruments Inc. United States Information Technology 60 13 The TJX Companies Inc. United States Information Technology 60 13 The TJX Companies Inc. United States Information Technology 69 35 Uber Technologies Inc. United States Industrials 969 35 Uber Technologies Inc. United States Industrials 821 59 Under Armour Inc. Class A United States Consumer Discretionary 4,086 40 Valero Energy Corp. United States Energy 335 5 United States Financials 10 Verrein Pharmaceuticals Inc. United States Health Care 67 32 Vermilion Energy Inc. Canada Energy 355 5 Vertex Pharmaceuticals Inc. United States Health Care 67 32 Visa Inc. Class A United States Financials 318 102 Vich Holdings Ltd. Hong Kong Information Technology 900 7 Vulcan Materials Co. United States Materials 34 10 Wartsila OYJ Finland Industrials 739 15 West Fraser Timber Co. Ltd. Vero Ltd. Vero Ltd. Vero Ltd. Vero Ltd. Vero Ltd. Vero Ltd. Vere United States Information Technology 161 47 Vero Ltd. Vero Ltd. Vero Ltd. Vere Ltd. Vero Ltd. Ve						9
Santen Pharmaceutical Co. Ltd. Sarepta Therapeutics Inc. United States Segyung Hitech Co. Ltd. South Korea Information Technology I,545 I5 SIA Engineering Co. Ltd. South Korea Information Technology I,545 I5 SIA Engineering Co. Ltd. Singapore Industrials G,300 I5 Skyworks Solutions Inc. United States Information Technology If Idea Information Informati	•					26
Sarepta Therapeutics Inc. United States Segyung Hitech Co. Ltd. South Korea Information Technology 1,545 15 SIA Engineering Co. Ltd. Singapore Industrials 6,300 15 Skyworks Solutions Inc. United States Information Technology 61 9 Stantec Inc. Canada Industrials 659 58 Subaru Corp. Japan Consumer Discretionary 2,400 60 Target Corp. United States Consumer Staples 337 63 TeamViewer AG Germany Information Technology 61 13 The TIX Companies Inc. United States Information Technology 60 13 The TIX Companies Inc. United States Information Technology 60 13 The TIX Companies Inc. United States Industrials 969 35 Uber Technologies Inc. United States Industrials 969 36 Uber Technologies Inc. United States Industrials 969 35 Uber Technologies 10 Technologies 11 Technologies 11 Technologies 12 Technologies 13 Technologies 14 Technologies 14 Technologies 15 Technologies 16 Technologies 16 Technologies 17 Technologies 17 Technologies 18 Technologies 19 Technologies 10 Technologies 11 Technologies 11 Technologies 11 Technologies 11 Technologies 11 Technologies 1						10
Segung Hitech Co. Ltd.South KoreaInformation Technology1,54515SIA Engineering Co. Ltd.SingaporeIndustrials6,30015Stantec Inc.United StatesInformation Technology619Stantec Inc.CanadaInformation Technology58Subaru Corp.JapanConsumer Discretionary2,40060Target Corp.United StatesConsumer Staples33763TeamViewer AGGermanyInformation Technology2,02340Texas Instruments Inc.United StatesInformation Technology6013The TUX Companies Inc.United StatesConsumer Discretionary39548Trelleborg ABSwedenIndustrials96935Uber Technologies Inc.United StatesConsumer Discretionary39548Under Armour Inc. Class AUnited StatesConsumer Discretionary4,08640Valero Energy Corp.United StatesConsumer Discretionary4,08640Valero Energy Inc.CanadaEnergy23243Vermilion Energy Inc.CanadaEnergy355Vertex Pharmaceuticals Inc.United StatesHealth Care6732Visa Inc. Class AUnited StatesFinancials318102Vietch Holdings Ltd.Hong KongInformation Technology9007Vulcan Materials Co.United StatesMaterials3410Workd Materials Co.United States						3
SIA Engineering Co. Ltd. Skyworks Solutions Inc. United States Information Technology Information Informatio						16
Skyworks Solutions Inc.United StatesInformation Technology619Stantec Inc.CanadaIndustrials65958Subaru Corp.JapanConsumer Discretionary2,40060Target Corp.United StatesConsumer Staples33763TeamViewer AGGermanyInformation Technology2,02340Texas Instruments Inc.United StatesInformation Technology6013The TJX Companies Inc.United StatesConsumer Discretionary39548Trelleborg ABSwedenIndustrials96935Uber Technologies Inc.United StatesIndustrials82159Under Armour Inc. Class AUnited StatesConsumer Discretionary4,08640Valero Energy Corp.United StatesEnergy23243Vermilion Energy Inc.CanadaEnergy3555Verfex Pharmaceuticals Inc.United StatesHealth Care6732Visa Inc. Class AUnited StatesHealth Care6732Visa Inc. Class AUnited StatesHinformation Technology9007Vulcan Materials Co.United StatesMaterials3410West Fraser Timber Co. Ltd.CanadaMaterials47151Workday Inc. Class AUnited StatesInformation Technology16147Workday Inc. Class AUnited StatesInformation Technology16147Workday Inc. Class AUnited States	6, 6					14
Stantec Inc.Canada Subaru Corp.IdapanConsumer Discretionary 1,40058Subaru Corp.United States GermanyConsumer Staples 1,607337 1,6363TeamViewer AG TeamViewer AG Team Viewer AG Team United States The TJX Companies Inc.United States United States United StatesInformation Technology 1,002 1,003 1,003 1,003 1,003 1,003 1,003 						9
Subaru Corp.Japan Target Corp.Consumer Discretionary Consumer Staples2,400 33760Target Corp.United StatesConsumer Staples33763Team Viewer AGGermanyInformation Technology2,02340Texas Instruments Inc.United StatesInformation Technology6013The TJX Companies Inc.United StatesConsumer Discretionary39548Trelleborg ABSwedenIndustrials96935Uber Technologies Inc.United StatesIndustrials82159Under Armour Inc. Class AUnited StatesConsumer Discretionary4,08640Valero Energy Corp.United StatesConsumer Discretionary4,08640Vermilion Energy Inc.CanadaEnergy23243Vermilion Energy Inc.CanadaEnergy3555Vertex Pharmaceuticals Inc.United StatesHealth Care6732Visa Inc. Class AUnited StatesFinancials318102Vican Materials Co.United StatesMaterials3410Vulcan Materials Co.United StatesMaterials3410West Fraser Timber Co. Ltd.CanadaMaterials47151Workday Inc. Class AUnited StatesInformation Technology16147Workday Inc. Class AUnited StatesInformation Technology60663	• •		6,5			74
Target Corp. Target Corp. United States Germany Information Technology Cexas Instruments Inc. United States Information Technology Information I						74
TeamViewer AG Texas Instruments Inc. United States Information Technology Information Industrials Information Industrials Information Industrials Information Industrials Information Industrials Information Infor						81
Texas Instruments Inc. United States United States Consumer Discretionary 395 48 Trelleborg AB Sweden United States Ubrechnologies Inc. United States Ubrechnologies Inc. United States Ubrechnologies Inc. United States Energy 232 43 Vermilion Energy Inc. United States United States United States Health Care 67 32 Visa Inc. Class A United States Health Care 67 32 Visa Inc. Class A United States Health Care 67 32 Visa Inc. Class A United States Financials 318 102 Viech Holdings Ltd. Viech Holdings Ltd. Vinited States Materials United States Materials Materials Materials Materials Mory Morik Materials Co. Ltd. United States Materials Morik Materials Morkday Inc. Class A United States Information Technology 161 47 Vero Ltd. New Zealand Information Technology 161 47 Vero Ltd. New Zealand Information Technology 163 63						41
The TJX Companies Inc. United States Sweden Industrials 1969 35 Uber Technologies Inc. United States Energy 232 43 Vermillon Energy Inc. United States United States Energy 355 5 Vertex Pharmaceuticals Inc. United States Health Care 67 32 Visa Inc. Class A United States Health Care 67 32 Visa Inc. Class A United States Financials 318 102 VTech Holdings Ltd. Hong Kong Information Technology 900 7 Vulcan Materials Co. United States Materials 34 10 Wartsila OYJ Finland Industrials 739 15 West Fraser Timber Co. Ltd. Vonik Materials Co. Ltd. Vonik Materials Co. Ltd. Vorkday Inc. Class A United States Information Technology 161 47 Xero Ltd. New Zealand Information Technology 606 63			6,7	•		14
Trelleborg AB Sweden Industrials 969 35 Uber Technologies Inc. United States Industrials 821 59 Under Armour Inc. Class A United States Consumer Discretionary 4,086 40 Valero Energy Corp. United States Energy 232 43 Vermilion Energy Inc. Canada Energy 355 5 Vertex Pharmaceuticals Inc. United States Health Care 67 32 Visa Inc. Class A United States Financials 318 102 Visa Inc. Class A United States Financials 318 102 Viech Holdings Ltd. Hong Kong Information Technology 900 7 Vulcan Materials Co. United States Materials 34 10 Wartsila OYJ Finland Industrials 739 15 West Fraser Timber Co. Ltd. South Korea Materials 439 14 Workday Inc. Class A United States Information Technology 161 47 Xero Ltd. New Zealand Information Technology 606 63						54
Uber Technologies Inc.United StatesIndustrials82159Under Armour Inc. Class AUnited StatesConsumer Discretionary4,08640Valero Energy Corp.United StatesEnergy23243Vermilion Energy Inc.CanadaEnergy3555Vertex Pharmaceuticals Inc.United StatesHealth Care6732Visa Inc. Class AUnited StatesFinancials318102VTech Holdings Ltd.Hong KongInformation Technology9007Vulcan Materials Co.United StatesMaterials3410Wartsila OYJFinlandIndustrials73915West Fraser Timber Co. Ltd.CanadaMaterials47151Wonik Materials Co. Ltd.South KoreaMaterials43914Workday Inc. Class AUnited StatesInformation Technology16147Xero Ltd.New ZealandInformation Technology60663	to the state of th					
Unider Armour Înc. Class AUnited StatesConsumer Discretionary4,08640Valero Energy Corp.United StatesEnergy23243Vermilion Energy Inc.CanadaEnergy3555Vertex Pharmaceuticals Inc.United StatesHealth Care6732Visa Inc. Class AUnited StatesFinancials318102VIEch Holdings Ltd.Hong KongInformation Technology9007Vulcan Materials Co.United StatesMaterials3410Wartsila OYJFinlandIndustrials73915West Fraser Timber Co. Ltd.CanadaMaterials47151Wonik Materials Co. Ltd.South KoreaMaterials43914Workday Inc. Class AUnited StatesInformation Technology16147Xero Ltd.New ZealandInformation Technology60663						47 96
Valero Energy Corp.United StatesEnergy23243Vermilion Energy Inc.CanadaEnergy3555Vertex Pharmaceuticals Inc.United StatesHealth Care6732Visa Inc. Class AUnited StatesFinancials318102VTech Holdings Ltd.Hong KongInformation Technology9007Vulcan Materials Co.United StatesMaterials3410Wartsila OYJFinlandIndustrials73915West Fraser Timber Co. Ltd.CanadaMaterials47151Wonik Materials Co. Ltd.South KoreaMaterials43914Workday Inc. Class AUnited StatesInformation Technology16147Xero Ltd.New ZealandInformation Technology60663						86
Vermilion Energy Inc.CanadaEnergy3555Vertex Pharmaceuticals Inc.United StatesHealth Care6732Visa Inc. Class AUnited StatesFinancials318102VTech Holdings Ltd.Hong KongInformation Technology9007Vulcan Materials Co.United StatesMaterials3410Wartsila OYJFinlandIndustrials73915West Fraser Timber Co. Ltd.CanadaMaterials47151Wonik Materials Co. Ltd.South KoreaMaterials43914Workday Inc. Class AUnited StatesInformation Technology16147Xero Ltd.New ZealandInformation Technology60663						41
Vertex Pharmaceuticals Inc.United StatesHealth Care6732Visa Inc. Class AUnited StatesFinancials318102VTech Holdings Ltd.Hong KongInformation Technology9007Vulcan Materials Co.United StatesMaterials3410Wartsila OYJFinlandIndustrials73915West Fraser Timber Co. Ltd.CanadaMaterials47151Wonik Materials Co. Ltd.South KoreaMaterials43914Workday Inc. Class AUnited StatesInformation Technology16147Xero Ltd.New ZealandInformation Technology60663						54
Visa Inc. Class AUnited StatesFinancials318102VTech Holdings Ltd.Hong KongInformation Technology9007Vulcan Materials Co.United StatesMaterials3410Wartsila OYJFinlandIndustrials73915West Fraser Timber Co. Ltd.CanadaMaterials47151Wonik Materials Co. Ltd.South KoreaMaterials43914Workday Inc. Class AUnited StatesInformation Technology16147Xero Ltd.New ZealandInformation Technology60663						6
VTech Holdings Ltd.Hong KongInformation Technology9007Vulcan Materials Co.United StatesMaterials3410Wartsila OYJFinlandIndustrials73915West Fraser Timber Co. Ltd.CanadaMaterials47151Wonik Materials Co. Ltd.South KoreaMaterials43914Workday Inc. Class AUnited StatesInformation Technology16147Xero Ltd.New ZealandInformation Technology60663						38
Vulcan Materials Co.United StatesMaterials3410Wartsila OYJFinlandIndustrials73915West Fraser Timber Co. Ltd.CanadaMaterials47151Wonik Materials Co. Ltd.South KoreaMaterials43914Workday Inc. Class AUnited StatesInformation Technology16147Xero Ltd.New ZealandInformation Technology60663						120
Wartsila OYJ Finland Industrials 739 15 West Fraser Timber Co. Ltd. Canada Materials 471 51 Wonik Materials Co. Ltd. South Korea Materials 439 14 Workday Inc. Class A United States Information Technology 161 47 Xero Ltd. New Zealand Information Technology 606 63						7
West Fraser Timber Co. Ltd. Canada Materials Vonik Materials Co. Ltd. South Korea Materials 439 14 Workday Inc. Class A United States Information Technology 161 47 Xero Ltd. New Zealand Information Technology 606 63						13
Wonik Materials Co. Ltd. South Korea Materials 439 14 Workday Inc. Class A United States Information Technology 161 47 Xero Ltd. New Zealand Information Technology 606 63						15
Workday Inc. Class A United States Information Technology 161 47 Xero Ltd. New Zealand Information Technology 606 63						55
Xero Ltd. New Zealand Information Technology 606 63						16
			6,5			59
		New Zealand	Information Technology	606 _		71
Total equities 6,381 7	Total equities				6,381	7,702

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

SCHEDULE OF INVESTMENTS (cont'd)

as at March 31, 2024

	Country	Sector	Par Value/ Number of Shares/Units	Average Cost (\$ 000)	Fair Value (\$ 000)
Transaction costs Total investments			=	(4) 6,377	7,702
Cash and cash equivalents Other assets less liabilities Net assets attributable to securityholders				_	492 (219) 7,975

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

SUMMARY OF INVESTMENT PORTFOLIO

MARCH 31, 2024

PORTFOLIO ALLOCATION	% OF NAV
Equities	96.5
Cash and cash equivalents	6.2
Other assets (liabilities)	(2.7)

REGIONAL ALLOCATION	% OF NAV
United States	73.5
Cash and cash equivalents	6.2
Canada	4.0
United Kingdom	3.9
South Korea	2.7
Denmark	2.5
Australia	2.2
Japan	2.1
Other	1.1
New Zealand	1.1
Switzerland	0.9
Sweden	0.6
Italy	0.5
Germany	0.5
Ireland	0.5
Norway	0.4
Other assets (liabilities)	(2.7)

SECTOR ALLOCATION	% OF NAV
Information technology	36.6
Health care	13.7
Consumer discretionary	11.4
Industrials	10.7
Communication services	8.2
Cash and cash equivalents	6.2
Consumer staples	6.1
Financials	4.0
Materials	3.3
Energy	2.3
Utilities	0.2
Other assets (liabilities)	(2.7)

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

1. Fiscal Periods and General Information

The information provided in these financial statements and notes thereto is for the period ended or as at March 31, 2024, as applicable. In the year a Fund or series is established or reinstated, 'period' represents the period from inception or reinstatement. Where a series of a Fund was terminated during either period, the information for the series is provided up to close of business on the termination date. Refer to Note 10 for the formation date of the Fund and the inception date of each series.

The Fund is organized as an open-ended mutual fund trust established under the laws of the Province of Ontario pursuant to a Declaration of Trust as amended and restated from time to time. The address of the Fund's registered office is 180 Queen Street West, Toronto, Ontario, Canada. The Fund is authorized to issue an unlimited number of units (referred to as "security" or "securities") of multiple series. Series of the Fund are available for sale under Simplified Prospectus or exempt distribution options.

Mackenzie Financial Corporation ("Mackenzie") is the manager and promoter of the Fund. Mackenzie is wholly owned by IGM Financial Inc., a subsidiary of Power Corporation of Canada. Canada Life Investment Management Ltd. ("CLIML") is wholly owned by The Canada Life Assurance Company ("Canada Life"), a subsidiary of Power Corporation of Canada. Investments in companies within the Power Group of companies held by the Fund are identified in the Schedule of Investments.

The Fund is exclusively distributed by PFSL Investments Canada Ltd. (the "Distributor").

2. Basis of Preparation and Presentation

These audited annual financial statements ("financial statements") have been prepared in accordance with IFRS Accounting Standards ("IFRS"). A summary of the Fund's material accounting policies under IFRS is presented in Note 3.

These financial statements are presented in Canadian dollars, which is the Fund's functional and presentation currency, and rounded to the nearest thousand unless otherwise indicated. These financial statements are prepared on a going concern basis using the historical cost basis, except for financial instruments that have been measured at fair value.

These financial statements were authorized for issue by the Board of Directors of Mackenzie Financial Corporation on June 4, 2024.

3. Material Accounting Policies

The Fund adopted Disclosure of Accounting Policies Amendments to IAS 1 and IFRS Practice Statements 2 from April 1, 2023. Although the amendments did not result in any changes to the accounting policies themselves, they impacted the accounting policy information disclosed in the financial statements. The amendments require the disclosure of 'material' rather than 'significant' accounting policies. The amendments also provide guidance on the application of materiality to disclosure of accounting policies. The Manager reviewed the accounting policies and made updates to the information disclosed in certain instances in line with the amendments.

(a) Financial instruments

Financial instruments include financial assets and liabilities such as debt and equity securities, investment funds and derivatives. The Fund classifies and measures financial instruments in accordance with IFRS 9, *Financial Instruments* ("IFRS 9"). Upon initial recognition, financial instruments are classified as fair value through profit or loss ("FVTPL"). All financial instruments are recognized in the Statement of Financial Position when the Fund becomes a party to the contractual requirements of the instrument. Financial assets are derecognized when the right to receive cash flows from the instrument has expired or the Fund has transferred substantially all risks and rewards of ownership. Financial liabilities are derecognized when the obligation is discharged, cancelled or expires. Investment purchase and sale transactions are recorded as of the trade date.

Financial instruments are subsequently measured at FVTPL with changes in fair value recognized in the Statement of Comprehensive Income — Other changes in fair value of investments and other net assets — Net unrealized gain (loss).

The cost of investments is determined on a weighted average cost basis.

Realized and unrealized gains and losses on investments are calculated based on the weighted average cost of investments and exclude commissions and other portfolio transaction costs, which are separately reported in the Statement of Comprehensive Income – Commissions and other portfolio transaction costs.

Gains and losses arising from changes in the fair value of the investments are included in the Statement of Comprehensive Income for the period in which they arise.

The Fund accounts for its holdings in unlisted open-ended investment funds, private funds ("Underlying Funds") and Exchange-Traded Funds ("ETFs"), if any, at FVTPL. For private funds, the Manager will rely on the valuations provided by the managers of the private funds, which represents the Fund's proportionate share of the net assets of these private funds. The Fund's investment in Underlying Funds and ETFs, if any, is presented in the Schedule of Investments at fair value which represents the Fund's maximum exposure on these investments.

The Fund's redeemable securities contain multiple dissimilar contractual obligations and entitle securityholders to the right to redeem their interest in the Fund for cash equal to their proportionate share of the net asset value of the Fund and therefore meet the criteria for classification as financial liabilities under IAS 32 Financial Instruments: Presentation. The Fund's obligation for net assets attributable to securityholders is presented at the redemption amount.

IAS 7, Statement of Cash Flows, requires disclosures related to changes in liabilities and assets, such as the securities of the Fund, arising from financing activities. Changes in securities of the Fund, including both changes from cash flows and non-cash changes, are included in the Statement of Changes in Financial Position. Any changes in the securities not settled in cash as at the end of the period are presented as either Accounts receivable for securities issued or Accounts payable for securities redeemed in the Statement of Financial Position. These accounts receivable and accounts payable amounts typically settle shortly after period-end.

(b) Fair value measurement

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

3. Material Accounting Policies (cont'd)

(b) Fair value measurement (cont'd)

Investments listed on a public securities exchange or traded on an over-the-counter market are valued on the basis of the last traded market price or closing price recorded by the security exchange on which the security is principally traded, where this price falls within the quoted bid-ask spread for the investment. In circumstances where this price is not within the bid-ask spread, Mackenzie determines the point within the bid-ask spread that is most representative of fair value based on the specific facts and circumstances. Mutual fund securities of an underlying fund are valued on a business day at the price calculated by the manager of such underlying fund in accordance with the constating documents of such underlying fund. Unlisted or non-exchange traded investments, or investments where a last sale or close price is unavailable or investments for which market quotations are, in Mackenzie's opinion, inaccurate, unreliable, or not reflective of all available material information, are valued at their fair value as determined by Mackenzie using appropriate and accepted industry valuation techniques including valuation models. The fair value determined using valuation models requires the use of inputs and assumptions based on observable market data including volatility and other applicable rates or prices. In limited circumstances, the fair value may be determined using valuation techniques that are not supported by observable market data.

Cash and cash equivalents which includes cash on deposit with financial institutions and short-term investments that are readily convertible to cash, are subject to an insignificant risk of changes in value, and are used by the Fund in the management of short-term commitments. Cash and cash equivalents are reported at fair value which closely approximates their amortized cost due to their nature of being highly liquid and having short terms to maturity. Bank overdraft positions are presented under current liabilities as bank indebtedness in the Statement of Financial Position.

The Fund may use derivatives (such as written options, futures, forward contracts, swaps or customized derivatives) to hedge against losses caused by changes in securities prices, interest rates or exchange rates. The Fund may also use derivatives for non-hedging purposes in order to invest indirectly in securities or financial markets, to gain exposure to other currencies, to seek to generate additional income, and/or for any other purpose considered appropriate by the Fund's portfolio manager(s), provided that the use of the derivative is consistent with the Fund's investment objectives. Any use of derivatives will comply with Canadian mutual fund laws, subject to the regulatory exemptions granted to the Fund, as applicable.

Valuations of derivative instruments are carried out daily, using normal exchange reporting sources for exchange-traded derivatives and specific broker enquiry for over-the-counter derivatives.

The value of forward contracts is the gain or loss that would be realized if, on the valuation date, the positions were to be closed out. The change in value of forward contracts is included in the Statement of Comprehensive Income — Other changes in fair value of investments and other net assets — Net unrealized gain (loss).

The daily fluctuation of futures contracts or swaps, along with daily cash settlements made by the Fund, where applicable, are equal to the change in unrealized gains or losses that are best determined at the settlement price. These unrealized gains or losses are recorded and reported as such until the Fund closes out the contract or the contract expires. Margin paid or deposited in respect of futures contracts or swaps is reflected as a receivable in the Statement of Financial Position — Margin on derivatives. Any change in the variation margin requirement is settled daily.

Premiums paid for purchasing an option are recorded in the Statement of Financial Position – Investments at fair value.

Premiums received from writing options are included in the Statement of Financial Position as a liability and subsequently adjusted daily to fair value. If a written option expires unexercised, the premium received is recognized as a realized gain. If a written call option is exercised, the difference between the proceeds of the sale plus the value of the premium, and the cost of the security is recognized as a realized gain or loss. If a written put option is exercised, the cost of the security acquired is the exercise price of the option less the premium received.

Refer to the Schedule of Derivative Instruments and Schedule of Options Purchased/Written, as applicable, included in the Schedule of Investments for a listing of derivative and options positions as at March 31, 2024.

The Fund categorizes the fair value of its assets and liabilities into three categories, which are differentiated based on the observable nature of the inputs and extent of estimation required.

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly. Examples of Level 2 valuations include quoted prices for similar securities, quoted prices on inactive markets and from recognized investment dealers, and the application of factors derived from observable data to non-North American quoted prices in order to estimate the impact of differences in market closing times.

Financial instruments classified as Level 2 investments are valued based on the prices provided by an independent reputable pricing services company who prices the securities based on recent transactions and quotes received from market participants and through incorporating observable market data and using standard market convention practices. Short-term investments classified as Level 2 investments are valued based on amortized cost plus accrued interest which closely approximates fair value.

The estimated fair values for these securities may be different from the values that would have been used had a ready market for the investment existed; and Level 3 – Inputs that are not based on observable market data.

The inputs are considered observable if they are developed using market data, such as publicly available information about actual events or transactions, and that reflect the assumption that market participants would use when pricing the asset or liability.

See Note 10 for the fair value classifications of the Fund.

(c) Income recognition

Interest income for distribution purposes represents the coupon interest received by the Fund which is accounted for on an accrual basis. The Fund does not amortize premiums paid or discounts received on the purchase of fixed income securities except for zero coupon bonds, which are amortized on a straight-line basis. Dividends are accrued as of the ex-dividend date. Unrealized gains or losses on investments, realized gains or losses on the sale of investments, including foreign exchange gains or losses on such investments, are calculated on a weighted average cost basis. Distributions received from an underlying fund are included in interest income, dividend income, realized gains (losses) on sale of investments or fee rebate income, as appropriate, on the ex-dividend or distribution date.

Income, realized gains (losses) and unrealized gains (losses) are allocated daily among the series on a pro-rata basis.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

3. Material Accounting Policies (cont'd)

(d) Commissions and other portfolio transaction costs

Commissions and other portfolio transaction costs are costs incurred to acquire, issue or dispose of financial assets or liabilities. They include fees and commissions paid to agents, exchanges, brokers, dealers and other intermediaries. The total brokerage commissions incurred by the Fund in connection with portfolio transactions for the periods, together with other transaction charges, is disclosed in the Statement of Comprehensive Income. Brokerage business is allocated to brokers based on the best net result for the Fund. Subject to this criteria, commissions may be paid to brokerage firms which provide (or pay for) certain services, other than order execution, which may include investment research, analysis and reports, and databases or software in support of these services. Where applicable and ascertainable, the value of these services generated during the periods is disclosed in Note 10. The value of certain proprietary services provided by brokers cannot be reasonably estimated.

(e) Securities lending, repurchase and reverse repurchase transactions

The Fund is permitted to enter into securities lending, repurchase and reverse repurchase transactions as set out in the Fund's Simplified Prospectus. These transactions involve the temporary exchange of securities for collateral with a commitment to redeliver the same securities on a future date.

Income is earned from these transactions in the form of fees paid by the counterparty and, in certain circumstances, interest paid on cash or securities held as collateral. Income earned from these transactions is included in the Statement of Comprehensive Income and recognized when earned. Securities lending transactions are administered by The Bank of New York Mellon (the "Securities Lending Agent"). The value of cash or securities held as collateral must be at least 102% of the fair value of the securities loaned, sold or purchased.

Note 10 summarizes the details of securities loaned and collateral received as at the end of period, as well as a reconciliation of securities lending income during the period, if applicable. Collateral received is comprised of debt obligations of the Government of Canada and other countries, Canadian provincial and municipal governments, and financial institutions.

(f) Offsetting

Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position only when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or to realize the asset and settle the liability simultaneously. In the normal course of business, the Fund enters into various master netting agreements or similar agreements that do not meet the criteria for offsetting in the Statement of Financial Position but still allow for the related amounts to be set off in certain circumstances, such as bankruptcy or termination of the contracts. Note 10 summarizes the details of such offsetting, if applicable, subject to master netting arrangements or other similar agreements and the net impact to the Statement of Financial Position if all such rights were exercised.

Income and expenses are not offset in the Statement of Comprehensive Income unless required or permitted to by an accounting standard, as specifically disclosed in the IFRS policies of the Fund.

(g) Currency

The functional and presentation currency of the Fund is Canadian dollars. Foreign currency purchases and sales of investments and foreign currency dividend and interest income and expenses are translated to Canadian dollars at the rate of exchange prevailing at the time of the transactions.

Foreign exchange gains (losses) on purchases and sales of foreign currencies are included in the Statement of Comprehensive Income – Other changes in fair value of investments and other net assets – Net realized gain (loss).

The fair value of investments and other assets and liabilities, denominated in foreign currencies, are translated to Canadian dollars at the rate of exchange prevailing on each business day.

(h) Net assets attributable to securityholders per security

Net assets attributable to securityholders per security is computed by dividing the net assets attributable to securityholders of a series of securities on a business day by the total number of securities of the series outstanding on that day.

(i) Net asset value per security

The daily Net Asset Value ("NAV") of an investment fund may be calculated without reference to IFRS as per the Canadian Securities Administrators' ("CSA") regulations. The difference between NAV and Net assets attributable to securityholders (as reported in the financial statements), if any, is mainly due to differences in fair value of investments and other financial assets and liabilities and is disclosed in Note 10.

(j) Increase (decrease) in net assets attributable to securityholders from operations per security

Increase (decrease) in net assets attributable to securityholders from operations per security in the Statement of Comprehensive Income represents the increase (decrease) in net assets attributable to securityholders from operations for the period, divided by the weighted average number of securities outstanding during the period.

(k) Mergers

In a fund merger, the Fund acquires all of the assets and assumes all of the liabilities of the terminating fund at fair value in exchange for securities of the Fund on the effective date of the merger.

(I) Future accounting changes

The Fund has determined there are no material implications to the Fund's financial statements arising from IFRS issued but not yet effective.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

4. Critical Accounting Estimates and Judgments

The preparation of these financial statements requires management to make estimates and assumptions that primarily affect the valuation of investments. Estimates and assumptions are reviewed on an ongoing basis. Actual results may differ from these estimates.

The following discusses the most significant accounting judgments and estimates made in preparing the financial statements:

Use of Estimates

Fair value of securities not quoted in an active market

The Fund may hold financial instruments that are not quoted in active markets and are valued using valuation techniques that make use of observable data, to the extent practicable. Various valuation techniques are utilized, depending on a number of factors, including comparison with similar instruments for which observable market prices exist and recent arm's length market transactions. Key inputs and assumptions used are company specific and may include estimated discount rates and expected price volatilities. Changes in key inputs, could affect the reported fair value of these financial instruments held by the Fund.

Use of Judgments

Classification and measurement of investments

In classifying and measuring financial instruments held by the Fund, Mackenzie is required to make significant judgments in order to determine the most appropriate classification in accordance with IFRS 9. Mackenzie has assessed the Fund's business model, the manner in which all financial instruments are managed and performance evaluated as a group on a fair value basis, and concluded that FVTPL in accordance with IFRS 9 provides the most appropriate measurement and presentation of the Fund's financial instruments.

Functional currency

The Fund's functional and presentation currency is the Canadian dollar, which is the currency considered to best represent the economic effects of the Fund's underlying transactions, events and conditions taking into consideration the manner in which securities are issued and redeemed and how returns and performance by the Fund are measured.

Interest in unconsolidated structured entities

In determining whether an Underlying Fund or an ETF in which the Fund invests, but that it does not consolidate, meets the definition of a structured entity, Mackenzie is required to make significant judgments about whether these underlying funds have the typical characteristics of a structured entity. These Underlying Funds do meet the definition of a structured entity because:

I. The voting rights in the Underlying Funds are not dominant factors in deciding who controls them;

II. the activities of the Underlying Funds are restricted by their offering documents; and

III. the Underlying Funds have narrow and well-defined investment objectives to provide investment opportunities for investors while passing on the associated risks and rewards.

As a result, such investments are accounted for at FVTPL. Note 10 summarizes the details of the Fund's interest in these Underlying Funds, if applicable.

5. Income Taxes

The Fund qualifies as a mutual fund trust under the provisions of the Income Tax Act (Canada) and, accordingly, is subject to tax on its income including net realized capital gains in the taxation year, which is not paid or payable to its securityholders as at the end of the taxation year. The Fund maintains a December year-end for tax purposes. The Fund may be subject to withholding taxes on foreign income. In general, the Fund treats withholding tax as a charge against income for tax purposes. The Fund will distribute sufficient amounts from net income for tax purposes, as required, so that the Fund will not pay income taxes other than refundable tax on capital gains, if applicable.

Losses of the Fund cannot be allocated to investors and are retained in the Fund for use in future years. Non-capital losses may be carried forward up to 20 years to reduce taxable income and realized capital gains of future years. Capital losses may be carried forward indefinitely to reduce future realized capital gains. Refer to Note 10 for the Fund's loss carryforwards.

6. Management Fees and Operating Expenses

Mackenzie is paid a management fee for managing the investment portfolio, providing investment analysis and recommendations, making investment decisions, making brokerage arrangements relating to the purchase and sale of the investment portfolio and making arrangements with registered dealers for the purchase and sale of securities of the Fund by investors. Mackenzie pays a portion of the management fees to the Distributor as compensation for its services to us and the Funds. The management fee is calculated on each series of securities of the Fund as a fixed annual percentage of the daily net asset value of the series.

Each series of the Fund is charged a fixed rate annual administration fee ("Administration Fee") and in return, Mackenzie bears all of the operating expenses of the Fund, other than certain specified fund costs. The Administration Fee is calculated on each series of securities of the Fund as a fixed annual percentage of the daily net asset value of the series.

Other fund costs include taxes (including, but not limited to GST/HST and income tax), interest and borrowing costs, all fees and expenses of the Mackenzie Funds' Independent Review Committee (IRC), costs of complying with the regulatory requirement to produce Fund Facts, fees paid to external service providers associated with tax reclaims, refunds or the preparation of foreign tax reports on behalf of the Funds, new fees related to external services that were not commonly charged in the Canadian mutual fund industry and introduced after the date of the most recently filed simplified prospectus, and the costs of complying with any new regulatory requirements, including, without limitation, any new fees introduced after the date of the most recently filed simplified prospectus.

Mackenzie may waive or absorb management fees and/or Administration Fees at its discretion and stop waiving or absorbing such fees at any time without notice. Refer to Note 10 for the management fee and Administration Fee rates charged to each series of securities.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

7. Fund's Capital

The capital of the Fund, which is comprised of the net assets attributable to securityholders, is divided into different series with each series having an unlimited number of securities. The securities outstanding for the Fund as at March 31, 2024 and securities issued, reinvested and redeemed for the period are presented in the Statement of Changes in Financial Position. Mackenzie manages the capital of the Fund in accordance with the investment objectives as discussed in Note 10.

8. Financial Instruments Risk

i. Risk exposure and management

The Fund's investment activities expose it to a variety of financial risks, as defined in IFRS 7, *Financial Instruments: Disclosures* ("IFRS 7"). The Fund's exposure to financial risks is concentrated in its investments, which are presented in the Schedule of Investments, as at March 31, 2024, grouped by asset type, with geographic and sector information.

Mackenzie seeks to minimize potential adverse effects of financial risks on the Fund's performance by employing professional, experienced portfolio advisors, by monitoring the Fund's positions and market events daily, by diversifying the investment portfolio within the constraints of the Fund's investment objectives, and where applicable, by using derivatives to hedge certain risk exposures. To assist in managing risks, Mackenzie also maintains a governance structure that oversees the Fund's investment activities and monitors compliance with the Fund's stated investment strategy, internal guidelines, and securities regulations.

ii. Liquidity risk

Liquidity risk arises when the Fund encounters difficulty in meeting its financial obligations as they become due. The Fund is exposed to liquidity risk due to potential daily cash redemptions of redeemable securities. In order to monitor the liquidity of its assets, the Fund utilizes a liquidity risk management program that calculates the number of days to convert the investments held by the Fund into cash using a multi-day liquidation approach. This liquidity risk analysis assesses the Fund's liquidity against predetermined minimum liquidity percentages established for different time periods and is monitored quarterly. In addition, the Fund has the ability to borrow up to 5% of its net assets for the purposes of funding redemptions.

In order to comply with securities regulations, the Fund must maintain at least 85% of its assets in liquid investments (i.e., investments that can be readily sold).

iii. Currency risk

Currency risk is the risk that financial instruments which are denominated or exchanged in a currency other than the Canadian dollar, which is the Fund's functional currency, will fluctuate due to changes in exchange rates. Generally, foreign denominated investments increase in value when the value of the Canadian dollar (relative to foreign currencies) falls. Conversely, when the value of the Canadian dollar rises relative to foreign currencies, the values of foreign denominated investments fall

Note 10 indicates the foreign currencies, if applicable, to which the Fund had significant exposure, including both monetary and non-monetary financial instruments, and illustrates the potential impact, in Canadian dollar terms, to the Fund's net assets had the Canadian dollar strengthened or weakened by 5% relative to all foreign currencies, all other variables held constant. In practice, the actual trading results may differ and the difference could be material.

The Fund's sensitivity to currency risk illustrated in Note 10 includes potential indirect impacts from underlying funds and ETFs in which the Fund invests, and/or derivative contracts including forward currency contracts. Other financial assets and liabilities (including dividends and interest receivable, and receivables/payables for investments sold/purchased) that are denominated in foreign currencies do not expose the Fund to significant currency risk.

iv. Interest rate risk

Interest rate risk arises on interest-bearing financial instruments. The Fund is exposed to the risk that the value of interest-bearing financial instruments will fluctuate due to changes in the prevailing levels of market interest rates. Generally, these securities increase in value when interest rates fall and decrease in value when interest rates rise.

If significant, Note 10 summarizes the Fund's interest-bearing financial instruments by remaining term to maturity and illustrates the potential impact to the Fund's net assets had prevailing interest rates increased or decreased by 1%, assuming a parallel shift in the yield curve, all other variables held constant. The Fund's sensitivity to interest rate changes was estimated using weighted average duration. In practice, the actual trading results may differ and the difference could be material.

The Fund's sensitivity to interest rate risk illustrated in Note 10 includes potential indirect impacts from underlying funds and ETFs in which the Fund invests, and/or derivative contracts. Cash and cash equivalents and other money market instruments are short term in nature and are not generally subject to significant amounts of interest rate risk.

v. Other price risk

Other price risk is the risk that the value of financial instruments will fluctuate as a result of changes in market prices (other than those arising from interest rate risk or currency risk), whether caused by factors specific to an individual investment, its issuer, or all factors affecting all instruments traded in a market or market segment. All investments present a risk of loss of capital. This risk is managed through a careful selection of investments and other financial instruments within the parameters of the investment strategies. Except for certain derivative contracts, the maximum risk resulting from financial instruments is equivalent to their fair value. The maximum risk of loss on certain derivative contracts such as forwards, swaps, and futures contracts is equal to their notional values. In the case of written call (put) options and short futures contracts, the loss to the Fund continues to increase, theoretically without limit, as the fair value of the underlying interest increases (decreases). However, these instruments are generally used within the overall investment management process to manage the risk from the underlying investments and do not typically increase the overall risk of loss to the Fund. This risk is mitigated by ensuring that the Fund holds a combination of the underlying interest, cash cover and/or margin that is equal to or greater than the value of the derivative contract.

Other price risk typically arises from exposure to equity and commodity securities. If significant, Note 10 illustrates the potential increase or decrease in the Fund's net assets, had the prices on the respective exchanges for these securities increased or decreased by 10%, all other variables held constant. In practice, the actual trading results may differ and the difference could be material.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

Financial Instruments Risk (cont'd)

v. Other price risk (cont'd)

The Fund's sensitivity to other price risk illustrated in Note 10 includes potential indirect impacts from underlying funds and ETFs in which the Fund invests, and/or derivative contracts.

vi. Credit risk

Credit risk is the risk that a counterparty to a financial instrument will fail to discharge an obligation or commitment that it has entered into with the Fund. Note 10 summarizes the Fund's exposure, if applicable and significant, to credit risk.

If presented, credit ratings and rating categories are based on ratings issued by a designated rating organization. Indirect exposure to credit risk may arise from fixedincome securities, such as bonds, held by underlying funds and ETFs, if any. The fair value of debt securities includes consideration of the creditworthiness of the debt issuer.

To minimize the possibility of settlement default, securities are exchanged for payment simultaneously, where market practices permit, through the facilities of a central depository and/or clearing agency where customary.

The carrying amount of investments and other assets represents the maximum credit risk exposure as at the date of the Statement of Financial Position. The Fund may enter into securities lending transactions with counterparties and it may also be exposed to credit risk from the counterparties to the derivative instruments it may use. Credit risk associated with these transactions is considered minimal as all counterparties have a rating equivalent to a designated rating organization's credit rating of not less than A-1 (low) on their short-term debt and of A on their long-term debt, as applicable.

vii. Underlying funds

The Fund may invest in underlying funds and may be indirectly exposed to currency risk, interest rate risk, other price risk and credit risk from fluctuations in the value of financial instruments held by the underlying funds. Note 10 summarizes the Fund's exposure, if applicable and significant, to these risks from underlying funds.

9. Other Information

Abbreviations

Foreign currencies, if any, are presented in these financial statements using the following abbreviated currency codes:

Currency Code	Description	Currency Code	Description	Currency Code	Description
AUD	Australian dollars	HUF	Hungarian forint	PLN	Polish zloty
AED	United Arab Emirates Dirham	IDR	Indonesian rupiah	QAR	Qatar Rial
BRL	Brazilian real	ILS	Israeli shekel	RON	Romanian leu
CAD	Canadian dollars	INR	Indian rupee	RUB	Russian ruble
CHF	Swiss franc	JPY	Japanese yen	SAR	Saudi riyal
CZK	Czech koruna	KOR	South Korean won	SEK	Swedish krona
CLP	Chilean peso	MXN	Mexican peso	SGD	Singapore dollars
CNY	Chinese yuan	MYR	Malaysian ringgit	ТНВ	Thailand baht
СОР	Colombian peso	NGN	Nigerian naira	TRL	Turkish lira
DKK	Danish krone	NOK	Norwegian krona	USD	United States dollars
EGP	Egyptian pound	NTD	New Taiwan dollar	VND	Vietnamese dong
EUR	Euro	NZD	New Zealand dollars	ZAR	South African rand
GBP	United Kingdom pounds	PEN	Peruvian nuevo sol	ZMW	Zambian kwacha
GHS	Ghana Cedi	PHP	Philippine peso		•
HKD	Hong Kong dollars	PKR	Pakistani rupee		

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

10. Fund Specific Information (in '000, except for (a))

(a) Fund Formation and Series Information

Date of Formation: June 27, 2023

The Fund may issue an unlimited number of securities of each series. The number of issued and outstanding securities of each series is disclosed in the Statement of Changes in Financial Position.

Series Distributed by PFSL Investments Canada Ltd. (6985 Financial Drive, Suite 400, Mississauga, Ontario, L5N 0G3; www.mackenzieinvestments.com/en/primerica)
PFSL Investments Canada Ltd. ("PFSL") is the principal distributor of the series of securities listed below:

Series PA securities are offered to retail investors investing a minimum of \$500 who have entered into an agreement with PFSL, which carries with it a specified dealer service fee.

Series PH securities are offered to certain high net worth investors investing a minimum of \$100,000 who have entered into an agreement with PFSL, which carries with it a specified dealer service fee.

	Inception/		
Series	Reinstatement Date	Management Fee	Administration Fee
Series PA	July 6, 2023	1.00%	0.30%
Series PH	July 6, 2023	0.80%	0.17%

(b) Tax Loss Carryforwards

Expiration Date of Non-Capital Losses

-	56	32	_													32	-
	Loss \$	Loss \$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	
	Capital	Non-Capital	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	
	Total	Total															

(c) Securities Lending

As at March 31, 2024, the Fund did not have any open securities lending, repurchase or reverse repurchase transactions.

(d) Commissions

	(\$)
March 31, 2024	1

(e) Risks Associated with Financial Instruments

i. Risk exposure and management

The Fund seeks long-term capital growth by investing primarily in a portfolio of Shariah-compliant equity securities of companies in developed-market countries anywhere in the world.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

- 10. Fund Specific Information (in '000, except for (a)) (cont'd)
- (e) Risks Associated with Financial Instruments (cont'd)

ii. Currency risk

The table below summarizes the Fund's exposure to currency risk.

			Marc	h 31, 2024				
			,			Impact on	net assets	
Currency	Investments (\$)	Cash and Short-Term Investments (\$)	Derivative Instruments (\$)	Net Exposure* (\$)	Strengther	ned by 5%	Weakene	d by 5% %
USD	5,869	6		5,875	(47	,,,	(+/	,,,
GBP	349	9	_	358				
AUD	246	6	_	252				
KOR	213	_	_	213				
DKK	200	9	_	209				
JPY	168	27	_	195				
EUR	142	6	_	148				
CHF	70	6	_	76				
SEK	47	6	_	53				
NOK	34	_	_	34				
SGD	25	_	_	25				
NZD	16	_	_	16				
HKD	7	_	_	7				
Total	7,386	75	_	7,461				
% of Net Assets	92.6	0.9	_	93.5				
Total currency rate sensitivi	ty				(373)	(4.7)	373	4.7

iii. Interest rate risk

As at March 31, 2024, the Fund did not have a significant exposure to interest rate risk.

iv. Other price risk

The table below summarizes the Fund's exposure to other price risk.

	10%	Decreased by 10%		
Impact on net assets	(\$)	(%)	(\$)	(%)
March 31, 2024	770	9.7	(770)	(9.7)

v. Credit risk

As at March 31, 2024, the Fund did not have a significant exposure to credit risk.

(f) Fair Value Classification

The table below summarizes the fair value of the Fund's financial instruments using the fair value hierarchy described in note 3.

		March 31, 2024					
	Level 1 (\$)	Level 2 (\$)	Level 3 (\$)	Total (\$)			
Equities	7,702	_	_	7,702			
Total	7,702	_	_	7,702			

The Fund's policy is to recognize transfers into and transfers out of fair value hierarchy levels as of the date of the event or change in circumstances that caused the transfer.

During the period ended March 31, 2024, non-North American equities frequently transferred between Level 1 (unadjusted quoted market prices) and Level 2 (adjusted market prices). As at March 31, 2024, these securities were classified as Level 1.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2024

NOTES TO FINANCIAL STATEMENTS

- 10. Fund Specific Information (in '000, except for (a)) (cont'd)
- (g) Investments by the Manager and Affiliates

The investments held by the Manager, other funds managed by the Manager, and funds managed by affiliates of the Manager, investing in series CL, IG or S of the Fund, as applicable (as described in *Fund Formation and Series Information* in note 10), were as follows:

	March 31, 2024
	(\$)
The Manager	4,715
Other funds managed by the Manager	_
Funds managed by affiliates of the Manager	_

- (h) Offsetting of Financial Assets and LiabilitiesAs at March 31, 2024, there were no amounts subject to offsetting.
- (i) Interest in Unconsolidated Structured Entities
 As at March 31, 2024, the Fund had no investments in Underlying Funds.